This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
World Health Organisation. Blood donor selection: guidelines on assessing donor suitability for blood donation. 2012.World Health Organisation. Blood donor selection: guidelines on assessing donor suitability for blood donation2012Search in Google Scholar
AABB technical manual, editor Fung MK 18th edition. 2014.AABB technical manual, editor Fung MK 18th edition2014Search in Google Scholar
World Health Organisation. Global status report on blood safety and availability. 2017.World Health Organisation. Global status report on blood safety and availability2017Search in Google Scholar
Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-504.ZouSDorseyKANotariEPFosterGAKrysztofDEMusaviFDoddRYStramerSLPrevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testingTransfusion201050149550410.1111/j.1537-2995.2010.02622.x20345570Search in Google Scholar
Picker SM. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus 2013; 11: 343-8.PickerSMCurrent methods for the reduction of blood-borne pathogens: a comprehensive literature reviewBlood Transfus2013113438Search in Google Scholar
Benjamin RJ. Pathogen inactivation – defining ‘adequate’ bacterial protection. American Red ISBT Science Series 2014; 9: 124–130.BenjaminRJPathogen inactivation – defining ‘adequate’ bacterial protectionAmerican Red ISBT Science Series2014912413010.1111/voxs.12057Search in Google Scholar
Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion 2015; 55: 2983–3000.KleinmanSStassinopoulosARisks associated with red blood cell transfusions: potential benefits from application of pathogen inactivationTransfusion2015552983300010.1111/trf.13259716985526303806Search in Google Scholar
Kirby Institute, UNSW Sydney, and the Austraian Red Cross Blood Service. Transfusion-trasmissible infections in Australia 2018 Surveillance report. 2018.Kirby Institute, UNSW Sydney, and the Austraian Red Cross Blood Service. Transfusion-trasmissible infections in Australia 2018 Surveillance report2018Search in Google Scholar
Haass KA, Sapiano MRP, Savinkina A, Kuehnert MJ, Basavaraju SV. Transfusion-trasmitted infections reported to the National Healthcare Safety Network Hemovigilance Module. Transfusion Medicine Reviews 2019; 33 (2): 84-91.HaassKASapianoMRPSavinkinaAKuehnertMJBasavarajuSVTransfusion-trasmitted infections reported to the National Healthcare Safety Network Hemovigilance ModuleTransfusion Medicine Reviews2019332849110.1016/j.tmrv.2019.01.001652016530930009Search in Google Scholar
Narayan S (Ed), Poles D et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steerin Group. The 2018 Annual SHOT Report. 2019.NarayanS(Ed), Poles D et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steerin GroupThe 2018 Annual SHOT Report2019Search in Google Scholar
Bolton-Maggs P (Ed), Poles D, et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2015 Annual SHOT Report. 2016.Bolton-MaggsP(Ed), Poles D, et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2015 Annual SHOT Report2016Search in Google Scholar
World Health Organisation. Screening donated blood for transfusion-trasmitted infections. 2010.World Health Organisation. Screening donated blood for transfusion-trasmitted infections2010Search in Google Scholar
Freimanis G, Sedegah M, Owusu-Ofori S, Kumar S, Allain JP. Investigating the prevalence of transfusion transmission of Plasmodium within hyperendemic blood donation system. Transfusion 2013; 53: 1429-41.FreimanisGSedegahMOwusu-OforiSKumarSAllainJPInvestigating the prevalence of transfusion transmission of Plasmodium within hyperendemic blood donation systemTransfusion20135314294110.1111/j.1537-2995.2012.03943.x23113534Search in Google Scholar
Busch MP, Bloch EM, Kleinman S. Prevention of Transfusion Transmitted Infections. Blood 2019; 133(17): 1854:1864.BuschMPBlochEMKleinmanSPrevention of Transfusion Transmitted InfectionsBlood2019133171854186410.1182/blood-2018-11-83399630808637Search in Google Scholar
Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, Cadden E, Coakley P. Screening platelet concentrates for bacterial contamination: low number of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95(1): 13-9.MurphyWGFoleyMDohertyCTierneyGKinsellaASalamiACaddenECoakleyPScreening platelet concentrates for bacterial contamination: low number of bacteria and slow growth in contaminated units mandate an alternative approach to product safetyVox Sang200895113910.1111/j.1423-0410.2008.01051.x18393945Search in Google Scholar
Drew VJ, Barro L, Seghatchian J, Burnouf T. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus 2017; 15: 512-21DrewVJBarroLSeghatchianJBurnoufTTowards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countriesBlood Transfus20171551221Search in Google Scholar
Dean CL, Wade J, Roback JD. Transfusion-trasmittes infections: an update on product screening, diagnostic techniques, and the path ahead. J Clin Microbiol 2018; 56: e00352-18.DeanCLWadeJRobackJDTransfusion-trasmittes infections: an update on product screening, diagnostic techniques, and the path aheadJ Clin Microbiol201856e003521810.1128/JCM.00352-18601832329669792Search in Google Scholar
Klein HG, Anderson D, Bernardi M, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti MLA, Smaill F. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338-2347.KleinHGAndersonDBernardiMCableRCareyWHochJSRobitailleNSivilottiMLASmaillFPathogen inactivation: making decisions about new technologiesReport of a consensus conference. Transfusion2007472338234710.1111/j.1537-2995.2007.01512.x18036075Search in Google Scholar
Seltsam A. Pathogen Inactivation of Cellular Blood Products - An Additional Safety Layer in Transfusion Medicine. Front Med 2017; 4: 219. doi:10.3389/fmed.2017.00219.SeltsamAPathogen Inactivation of Cellular Blood Products - An Additional Safety Layer in Transfusion MedicineFront Med2017421910.3389/fmed.2017.00219572278729255710Open DOISearch in Google Scholar
Atreya C, Glynn S, Busch M, Kleinman S, Snyder E, Rutter S, AuBuchon J, Flegel W, Reeve D, Devine D, Cohn C, Custer B, Goodrich R, Benjamin RJ, Razatos A, Cancelas J, Wagner S, Maclean M, Gelderman M, Cap A, Ness P. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018. Transfusion 2019; 29: doi: 10.1111/trf.15344.AtreyaCGlynnSBuschMKleinmanSSnyderERutterSAuBuchonJFlegelWReeveDDevineDCohnCCusterBGoodrichRBenjaminRJRazatosACancelasJWagnerSMacleanMGeldermanMCapANessPProceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018Transfusion20192910.1111/trf.15344Open DOISearch in Google Scholar
Ngo LT, Bruhn R, Custer B. Risk perception and its role in attitudes toward Blood Transfusion: a qualitative systematic review. Transfus Med Rev 2013; 27: 119-128.NgoLTBruhnRCusterBRisk perception and its role in attitudes toward Blood Transfusion: a qualitative systematic reviewTransfus Med Rev20132711912810.1016/j.tmrv.2013.02.003Search in Google Scholar
Merz EM, Zijlstra BJ, de Kort WL. Perceived blood transfusion safety: a cross-European comparison. Vox Sang 2016; 110: 258265.MerzEMZijlstraBJdeKort WLPerceived blood transfusion safety: a cross-European comparisonVox Sang201611025826510.1111/vox.12362Search in Google Scholar
van Doorn HR. Emerging infectious diseases. Medicine (Abingdon) 2014; 42(1): 60-63.vanDoorn HREmerging infectious diseasesMedicine (Abingdon)2014421606310.1016/j.mpmed.2013.10.014Search in Google Scholar
Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dood RY. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 Suppl 2: 1S-29S. doi: 10.1111/j.1537-2995.2009.02279.x.StramerSLHollingerFBKatzLMKleinmanSMetzelPSGregoryKRDoodRYEmerging infectious disease agents and their potential threat to transfusion safetyTransfusion200949 Suppl21S29S10.1111/j.1537-2995.2009.02279.xOpen DOISearch in Google Scholar
Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks – the globalization of vectorborne diseases. N Engl J Med 2007; 356: 769–771.CharrelRNdeLamballerie XRaoultDChikungunya outbreaks – the globalization of vectorborne diseasesN Engl J Med200735676977110.1056/NEJMp078013Search in Google Scholar
Stramer SL, Linnen JM, Carrick JM, Foster G, Krysztof DE, Zou S, Dodd RY, Tirado-Marrero LM, Hunsperger E, Santiago GA, Muñoz-Jordan JL, Tomashek KH. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52: 1657-66.StramerSLLinnenJMCarrickJMFosterGKrysztofDEZouSDoddRYTirado-MarreroLMHunspergerESantiagoGAMuñoz-JordanJLTomashekKHDengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto RicoTransfusion20125216576610.1111/j.1537-2995.2012.03566.xSearch in Google Scholar
Motta IJ, Spencer BR, Cordeiro da Silva SG, Arruda MB, Dobbin JA, Gonzaga YB, Arcuri IP, Tavares RC, Atta EH, Fernandes RF, Costa DA, Ribeiro LJ, Limonte F, Higa LM, Voloch CM, Brindeiro RM, Tanuri A, Ferreira O. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016; 375(11): 1101–3. doi:10.1056/ NEJMc1607262.MottaIJSpencerBRCordeiroda Silva SGArrudaMBDobbinJAGonzagaYBArcuriIPTavaresRCAttaEHFernandesRFCostaDARibeiroLJLimonteFHigaLMVolochCMBrindeiroRMTanuriAFerreiraOEvidence for transmission of Zika virus by platelet transfusionN Engl J Med2016375111101310.1056/NEJMc1607262Open DOISearch in Google Scholar
Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MH. Chikungunya: a re-emerging virus. Lancet 2012; 379: 662-71.BurtFJRolphMSRulliNEMahalingamSHeiseMHChikungunya: a re-emerging virusLancet20123796627110.1016/S0140-6736(11)60281-XSearch in Google Scholar
Petersen LR, Epstein JS, Chikungunya virus – new risk to transfusion safety in the Americas. Transfusion 2014; 54(8): 1911–1915. doi:10.1111/trf.12790.PetersenLREpsteinJSChikungunya virus – new risk to transfusion safety in the AmericasTransfusion20145481911191510.1111/trf.12790648283125130331Open DOISearch in Google Scholar
Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009; 49: 1083–91.RasonglesPAngelini-TibertMFSimonPCurrieCIsolaHKientzDSlaedtsMJacquetMSundinDLinLCorashLCazenaveJPTransfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La ReunionTransfusion20094910839110.1111/j.1537-2995.2009.02111.x19309473Search in Google Scholar
Laughhunn A, Huang YS, Vanlandingham DL, Lanteri MC, Stassinopoulos A. Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione. Transfusion 2018; 58: 748–757.LaughhunnAHuangYSVanlandinghamDLLanteriMCStassinopoulosAInactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathioneTransfusion20185874875710.1111/trf.1444229322519Search in Google Scholar
Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S, Leparc-Goffart I, Flusin O, Prat CM, Césaire R, Najioullah F, Ardillo V, Balleydier E, Carvalho L, Lamaître A, Noël H, Servas V, Six C, Zurbaran M, Léon L, Guinard A, van der Kerkhof J, Henry M, Fanoy E, Braks M, Reimerink J, Swaan C, Georges R, Brooks L, Freedman J, Sudre B, Zeller H. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill 2014;19(13):pii=20759VanBortel WDorleansFRosineJBlateauARoussetDMatheusSLeparc-GoffartIFlusinOPratCMCésaireRNajioullahFArdilloVBalleydierECarvalhoLLamaîtreANoëlHServasVSixCZurbaranMLéonLGuinardAvander Kerkhof JHenryMFanoyEBraksMReimerinkJSwaanCGeorgesRBrooksLFreedmanJSudreBZellerHChikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for EuropeEuro Surveill20141913pii=2075910.2807/1560-7917.ES2014.19.13.2075924721539Search in Google Scholar
Vairo F, Haider N, Kock R, Ntoumi F, ippolito G, Zumla A. Chikungunya: epidemiology, pathogenesis, clinicial features, management, and prevention. Infect Dis Clin North Am 2019; 33: 1003-1025.VairoFHaiderNKockRNtoumiFippolitoGZumlaAChikungunya: epidemiology, pathogenesis, clinicial features, management, and preventionInfect Dis Clin North Am2019331003102510.1016/j.idc.2019.08.00631668189Search in Google Scholar
Riccardo F, Venturi G, Di Luca M, Del Manso M, Severini F, Andrianou X, Fortuna C, Remoli ME, Benedetti E, Caporali MG, Fratto F, Mignuoli AD, Rizzo L, De Vito G, De Giorgio V, Surace L, Vairo F, Angelini P, Re MC, Amendola A, Fiorentini C, Marsili G, Toma L, Boccolini D, Romi R, Pezzotti P, Rezza G, Rizzo C. Secondary Autochthonous Outbreak of Chikungunya, Southern Italy, 2017. Emerg Infect Dis 2019; 25: 2093-2095RiccardoFVenturiGDiLuca MDelManso MSeveriniFAndrianouXFortunaCRemoliMEBenedettiECaporaliMGFrattoFMignuoliADRizzoLDeVito GDeGiorgio VSuraceLVairoFAngeliniPReMCAmendolaAFiorentiniCMarsiliGTomaLBoccoliniDRomiRPezzottiPRezzaGRizzoCSecondary Autochthonous Outbreak of ChikungunyaSouthern Italy2017Emerg Infect Dis 2019252093209510.3201/eid2511.180949681018731625839Search in Google Scholar
Calba C, Guerbois-Galla M, Franke F, Jeannin C, Auzet-Caillaud M, Grard G, Pigaglio L, Decoppet A, Weicherding J, Savaill MC, Munoz-Riviero M, Chaud P, Cadiou B, Ramalli L, Fournier P, Noël H, De Lamballerie X, Paty MC, Leparc-Goffart I. Preliminary report of an autochthonous chikungunya outbreak in France, July to September 2017. Euro Surveill 2017; 22: 17-00647.CalbaCGuerbois-GallaMFrankeFJeanninCAuzet-CaillaudMGrardGPigaglioLDecoppetAWeicherdingJSavaillMCMunoz-RivieroMChaudPCadiouBRamalliLFournierPNoëlHDeLamballerie XPatyMCLeparc-GoffartIPreliminary report of an autochthonous chikungunya outbreak in FranceJuly to September 2017. Euro Surveill201722170064710.2807/1560-7917.ES.2017.22.39.17-00647570995229019313Search in Google Scholar
Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, Guillaumont L, Griggs A, Bel M, Lambert AJ, Laven J, Kosoy O, anella A, Biggerstaff BJ, Fischer M, Hayes EB. Zika virus outbreak on Yap Island, Federated States OF Micronesia. N Engl J Med 2009; 360: 2536-2543.DuffyMRChenTHHancockWTPowersAMKoolJLLanciottiRSPretrickMMarfelMHolzbauerSDubrayCGuillaumontLGriggsABelMLambertAJLavenJKosoyOanellaABiggerstaffBJFischerMHayesEBZika virus outbreak on Yap Island, Federated States OF MicronesiaN Engl J Med20093602536254310.1056/NEJMoa080571519516034Search in Google Scholar
Chevalier MS, Biggerstaff BJ, Basavaraju SV, Bañez Ocfemia MC, Alsina JO, Climent-Peris C, Moseley RR, Chung K, Rivera-García B, Bello-Pagán M, Pate LL, Galel SA, Williamson P, Kuehnert MJ. Use of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April–August 2016. Emerg Infect Dis 2017; 23(5): 790-795.ChevalierMSBiggerstaffBJBasavarajuSVBañezOcfemia MCAlsinaJOCliment-PerisCMoseleyRRChungKRivera-GarcíaBBello-PagánMPateLLGalelSAWilliamsonPKuehnertMJUse of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April–August 2016Emerg Infect Dis 201723579079510.3201/eid2305.161873540302428263141Search in Google Scholar
Ferraris P, Yssel H, Missé D. Zika virus infection: an update. Microbes Infect 2019; 21(8-9): 353-360.FerrarisPYsselHMisséDZika virus infection: an updateMicrobes Infect2019218-935336010.1016/j.micinf.2019.04.00531158508Search in Google Scholar
Petersen LR, Brault AC, Nasci RS. West Nile Virus: Review of the Literature. JAMA. 2013; 17; 310(3): 308–315.PetersenLRBraultACNasciRSWest Nile Virus: Review of the LiteratureJAMA201317310330831510.1001/jama.2013.8042456398923860989Search in Google Scholar
Pisani G, Cristiano K, Pupella S, Liumbruno GM. West Nile Virus in Europe and Safety of Blood Transfusion.Transfus Med Hemother 2016;43(3): 158-67.PisaniGCristianoKPupellaSLiumbrunoGMWest Nile Virus in Europe and Safety of Blood TransfusionTransfus Med Hemother20164331586710.1159/000446219492447927403087Search in Google Scholar
Hayes C, Stephens L, Fridey JL, Snyder RE, Groves JA, Stramer SL, Klapper E. Probable transfusion transmission of West Nile virus from an apheresis platelet that screened non‐reactive by individual donor‐nucleic acid testing. Transfusion 2019; 9999: 1–6HayesCStephensLFrideyJLSnyderREGrovesJAStramerSLKlapperEProbable transfusion transmission of West Nile virus from an apheresis platelet that screened non‐reactive by individual donor‐nucleic acid testingTransfusion201999991610.1111/trf.1556831633814Search in Google Scholar
Seed CR, Kitchen A, Davis TM. The current status and potential role of laboratory testing to prevent transfusio-trasmitted malaria. Transfus Med Rev 2005; 19: 229-240.SeedCRKitchenADavisTMThe current status and potential role of laboratory testing to prevent transfusio-trasmitted malariaTransfus Med Rev20051922924010.1016/j.tmrv.2005.02.00416010653Search in Google Scholar
Mangano VD, Perandin F, Tiberti N, Guerriero M, Migliaccio F, Prato M, Bargagna L, Tais S, Degani M, Verra F, Bisoffi Z, Bruschi F. Risk of transfusion-transmitted malaria: evaluation of commercial ELISA kits for the detection of anti-Plasmodium antibodies in candidate blood donors Malar J. 2019; 18: 17.ManganoVDPerandinFTibertiNGuerrieroMMigliaccioFPratoMBargagnaLTaisSDeganiMVerraFBisoffiZBruschiFRisk of transfusion-transmitted malaria: evaluation of commercial ELISA kits for the detection of anti-Plasmodium antibodies in candidate blood donors Malar J2019181710.1186/s12936-019-2650-0634173630670018Search in Google Scholar
Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev 2002; 15: 66-78.MoodyARapid diagnostic tests for malaria parasitesClin Microbiol Rev200215667810.1128/CMR.15.1.66-78.200211806011781267Search in Google Scholar
Verra F, Angheben A, Martello E, Giorli G, Perandin F, Bisof Z. A systematic review of transfusion-transmitted malaria in non-endemic areas. Malar J (2018); 17: 36.VerraFAnghebenAMartelloEGiorliGPerandinFBisofZA systematic review of transfusion-transmitted malaria in non-endemic areasMalar J2018173610.1186/s12936-018-2181-0577118929338786Search in Google Scholar
World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases. 2013.World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases2013Search in Google Scholar
Guerri-Guttemberg RA, Grana DR, Ambrosio G, Milei J. Chagas cardiomyopathy: Europe is not spread! Eur Heart 2008; 29: 2587-91.Guerri-GuttembergRAGranaDRAmbrosioGMileiJChagas cardiomyopathy: Europe is not spread! Eur Heart20082925879110.1093/eurheartj/ehn42418840880Search in Google Scholar
World Health Organisation. Control and prevention of Chagas disease in Europe, Report of a WHO Informal Consultation (jointly organized by WHO headquarters and the WHO Regional Office for Euroe), Geneva, Switzerland 17-18 December 2009, 2010.World Health Organisation. Control and prevention of Chagas disease in Europe, Report of a WHO Informal Consultation (jointly organized by WHO headquarters and the WHO Regional Office for Euroe)Geneva, Switzerland17-18 December20092010Search in Google Scholar
Schmunis GA. Trypanosoma cruzi the etiological agent of Chagas’ disease as a contaminant of blood supplies. A problem of endemic and nonendemic countries. Transfusion 1991; 31: 547–557.SchmunisGATrypanosoma cruzi the etiological agent of Chagas’ disease as a contaminant of blood suppliesA problem of endemic and nonendemic countries. Transfusion19913154755710.1046/j.1537-2995.1991.31691306255.x1906650Search in Google Scholar
Benjamin RJ, Stramer SL, Leiby DA, Dodd RY, Fearon M, Castro E. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 2012; 52: 1913–1921.BenjaminRJStramerSLLeibyDADoddRYFearonMCastroETrypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmissionTransfusion2012521913192110.1111/j.1537-2995.2011.03554.x22321142Search in Google Scholar
Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, Gandini G, Aprili G. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus 2015; 13(4): 540–550.AnghebenABoixLBuonfrateDGobbiFBisoffiZPupellaSGandiniGApriliGChagas disease and transfusion medicine: a perspective from non-endemic countriesBlood Transfus2015134540550Search in Google Scholar
World Health Organization. WHO Consultation on International Biological Reference Preparations for Chagas Diagnostic Tests, Geneva, Switzerland 2-3 July 2007. 2007.World Health Organization. WHO Consultation on International Biological Reference Preparations for Chagas Diagnostic TestsGeneva, Switzerland2-3 July20072007Search in Google Scholar
Lidani KCF, Andrade FA, Bavia L, Damasceno FS, Beltrame MH, Messias-Reason IJ, Sandri TL. Chagas Disease: From Discovery to a Worldwide Health Problem. Front Public Health 2019; 7: 166.LidaniKCFAndradeFABaviaLDamascenoFSBeltrameMHMessias-ReasonIJSandriTLChagas Disease: From Discovery to a Worldwide Health ProblemFront Public Health2019716610.3389/fpubh.2019.00166661420531312626Search in Google Scholar
Cushing MM, Pagano MB, Jacobson J, Schwartz J, Grossman BJ, Kleinman S, Han MA, Cohn CS on behalf of the AABB Clinical Transfusion Medicine Committee. Pathogen reduced plasma products: a clinical practice scientific review from the AABB. Transfusion 2019; 59: 2974–2988.CushingMMPaganoMBJacobsonJSchwartzJGrossmanBJKleinmanSHanMACohnCS on behalf of the AABB Clinical Transfusion Medicine CommitteePathogen reduced plasma products: a clinical practice scientific review from the AABBTransfusion2019592974298810.1111/trf.1543531268584Search in Google Scholar
Lee LJ, Roland KJ, Sreenivasan GM, Zypchen LN, Ambler LS, Yenson PR. Solvent-Detergent Plasma for the Treatment of Thrombotic Microangiopathies: A Canadian Tertiary Care Centre Experience. Transfus Apher Sci 2018; 57(2): 233-235.LeeLJRolandKJSreenivasanGMZypchenLNAmblerLSYensonPRSolvent-Detergent Plasma for the Treatment of Thrombotic Microangiopathies: A Canadian Tertiary Care Centre ExperienceTransfus Apher Sci201857223323510.1016/j.transci.2018.02.00529496401Search in Google Scholar
Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virusinactivated substitute for fresh frozen plasma. Blood 1992; 79: 826-31.HorowitzBBonomoRPrinceAMChinSNBrotmanBShulmanRWSolvent/detergent-treated plasma: a virusinactivated substitute for fresh frozen plasmaBlood1992798263110.1182/blood.V79.3.826.826Search in Google Scholar
Restivo JSA, Karafin MS. Plasma products. In Transfusion medicine ane hemostasis (3th edition). Clinical and laboratory aspects. Elsevier 2019: 205-212.RestivoJSAKarafinMSPlasma productsInTransfusion medicine ane hemostasis (3th edition). Clinical and laboratory aspectsElsevier201920521210.1016/B978-0-12-813726-0.00034-9Search in Google Scholar
Pitkänen H, Jouppila A, Mowinckel MC, Lemponen M, Patiwael S, Sandset PR, Lassila R, Brinkman HJM. Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. Thrombosis Research 2015; 135: 167–174.PitkänenHJouppilaAMowinckelMCLemponenMPatiwaelSSandsetPRLassilaRBrinkmanHJMEnhanced thrombin generation and reduced intact protein S in processed solvent detergent plasmaThrombosis Research201513516717410.1016/j.thromres.2014.10.02025466844Search in Google Scholar
Doyle S, O’Brien P, Murphy K, Fleming C, O’Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003; 14(3): 283-7.DoyleSO’BrienPMurphyKFlemingCO’DonnellJCoagulation factor content of solvent/detergent plasma compared with fresh frozen plasmaBlood Coagul Fibrinolysis2003143283710.1097/01.mbc.0000061298.28953.7d12695752Search in Google Scholar
Marietta M, Franchini M, Bindi ML, Picardi F , Ruggeri M , De Silvestro G. Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document. Blood Transfus 2016; 14: 277-86.MariettaMFranchiniMBindiMLPicardiFRuggeriMDeSilvestro GIs solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus documentBlood Transfus20161427786Search in Google Scholar
Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion 2012; 52: 9S-19S.BenjaminRJMcLaughlinLSPlasma components: properties, differences, and usesTransfusion2012529S19S10.1111/j.1537-2995.2012.03622.x22578375Search in Google Scholar
Hellstern P, Solheim BG. The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma. Transfus Med Hemother 2011; 38(1): 65–70.HellsternPSolheimBGThe Use of Solvent/Detergent Treatment in Pathogen Reduction of PlasmaTransfus Med Hemother2011381657010.1159/000323552313298121779207Search in Google Scholar
Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40(10):1203-6.KoenigbauerUFEastlundTDayJWClinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasmaTransfusion200040101203610.1046/j.1537-2995.2000.40101203.x11061856Search in Google Scholar
EDQM (Council of Europe). Guide to the praparation, use and quality assurance of blood components. 19th ed. 2017.EDQM (Council of Europe). Guide to the praparation, use and quality assurance of blood components. 19th ed2017Search in Google Scholar
Fast LD, Di Leone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51: 1397-1404.FastLDDiLeone GMarschnerSInactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiationTransfusion2011511397140410.1111/j.1537-2995.2010.02984.x21155832Search in Google Scholar
Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011; 38(1): 19–31.IrschJLinLPathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood systemTransfus Med Hemother2011381193110.1159/000323937313297721779203Search in Google Scholar
Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496-504.LinLDikemanRMoliniBLukehartSALaneRDupuisKMetzelPCorashLPhotochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteriaTransfusion200444149650410.1111/j.1537-2995.2004.04125.x15383024Search in Google Scholar
Aubry M, Richard V, Green J, Broult J, Musso D. Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2016; 1: 33-40.AubryMRichardVGreenJBroultJMussoDInactivation of Zika virus in plasma with amotosalen and ultraviolet A illuminationTransfusion20161334010.1111/trf.1327126283013Search in Google Scholar
VanVoorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003; 47: 475–479.VanVoorhisWCBarrettLKEastmanRTAlfonsoRDupuisKTrypanosoma cruzi inactivation in human platelet concentrates and plasma by psoralen (amotosalen HCl) and long-wavelength UVAntimicrob Agents Chemother20034747547910.1128/AAC.47.2.475-479.200315174212543646Search in Google Scholar
Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Kupuis K. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008; 48: 1676–1684.GrellierPBenachJLabaiedMCharneauSGilHMonsalveGAlfonsoRSawyerLLinLSteiertMKupuisKPhotochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma componentsTransfusion2008481676168410.1111/j.1537-2995.2007.01762.x18503613Search in Google Scholar
Hauser L, Roque-Afonso AM, Beyloune A, Simonet M, Bénédicte Deau Fischer, Nicolas Burin des Roziers, Mallet V, Tiberghien P, Bierling P. Hepatitis E transmission by transfusion of Intercept blood system− treated plasma. Blood 2014; 123: 796-797.HauserLRoque-AfonsoAMBeylouneASimonetMBénédicteDeau FischerNicolasBurin des RoziersMalletVTiberghienPBierlingPHepatitis E transmission by transfusion of Intercept blood system− treated plasmaBlood201412379679710.1182/blood-2013-09-52434824482503Search in Google Scholar
Gowland P, Fontana S, Stolz M, Andina N, Niederhauser C. Parvovirus B19 passive transmission by transfusion of Intercept® blood system-treated platelet concentrate. Transfus Med Hemother 2016; 43: 198–202.GowlandPFontanaSStolzMAndinaNNiederhauserCParvovirus B19 passive transmission by transfusion of Intercept® blood system-treated platelet concentrateTransfus Med Hemother20164319820210.1159/000445195492446427403092Search in Google Scholar
Castro G, Merkel PA, Giclas HE, Gibula A, Andersen GE, Corash LM, Lin JS, Green J, Knight V, Stassinopoulos A. Amotosalen/ UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease Transfusion 2018; 58: 1506– 1515.CastroGMerkelPAGiclasHEGibulaAAndersenGECorashLMLinJSGreenJKnightVStassinopoulosAAmotosalen/ UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease Transfusion2018581506–151510.1111/trf.1458929607502Search in Google Scholar
Feys HB, Van Aelst B, Compernolle V. Biomolecular Consequences of Platelet Pathogen Inactivation Methods. Transfusion Medicine Reviews 2019; 33: 29–34.FeysHBVanAelst BCompernolleVBiomolecular Consequences of Platelet Pathogen Inactivation MethodsTransfusion Medicine Reviews201933293410.1016/j.tmrv.2018.06.00230021699Search in Google Scholar
Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80:15–21.KumarVLockerbieOKeilSDRuanePHPlatzMSMartinCBRavanatJLCadetJGoodrichRPRiboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular levelPhotochem Photobiol200480152110.1562/2003-12-23-RA-036.115339215Search in Google Scholar
Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38(1): 8–18.MarschnerSGoodrichRPathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV lightTransfus Med Hemother201138181810.1159/000324160Search in Google Scholar
Klein SD, Hovenga N, Gilmour D, Marschner S, Goodrich R. Treatment of platelet products with riboflavin and UV light: effectiveness against titer bacterial contamination. J Vis Exp 2015; (102): 52820. doi: 10.3791/52820 (2015)KleinSDHovengaNGilmourDMarschnerSGoodrichRTreatment of platelet products with riboflavin and UV light: effectiveness against titer bacterial contaminationJ Vis Exp20151025282010.3791/528202015Open DOISearch in Google Scholar
Allain J, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016; 387: 1753–61.AllainJOwusu-OforiAKAssennatoSMMarschnerSGoodrichRPOwusu-OforiSEffect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trialLancet201638717536110.1016/S0140-6736(16)00581-XSearch in Google Scholar
Chatterjee K, Zaman S, Chaurasia R, Singh S, Keil SD Tewari S, Bisht A, Agarwal N, Rout D, Chand S, Saha K. Evaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with Staphylococcus epidermidis A pilot study from India. Asian J Transfus Sci 2016; 10(2): 127–131.ChatterjeeKZamanSChaurasiaRSinghSKeilSD Tewari SBishtAAgarwalNRoutDChandSSahaKEvaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with Staphylococcus epidermidis A pilot study from IndiaAsian J Transfus Sci201610212713110.4103/0973-6247.187946499308127605849Search in Google Scholar
Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion 2016; 56; 2948–2952.KeilSDBowenRMarschnerSInactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatmentTransfusion2016562948–295210.1111/trf.13860716976527805261Search in Google Scholar
Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez, Reddy H, Goodrich R. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90: 85–91.CardoLJRentasFJKetchumLSalataJHarmanRMelvinWWeinaPJMendezReddy HGoodrichRPathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet lightVox Sang200690859110.1111/j.1423-0410.2005.00736.x16430665Search in Google Scholar
Faddy HM, Prow NA, Fryk JJ, Hall RA, Keil SA, Goodrich RP, Marks DC. The effect of riboflavin and ultraviolet light on the infectivity of arboviruses. Transfusion 2015; 55: 824–831.FaddyHMProwNAFrykJJHallRAKeilSAGoodrichRPMarksDCThe effect of riboflavin and ultraviolet light on the infectivity of arbovirusesTransfusion20155582483110.1111/trf.1289925370822Search in Google Scholar
Vanlandingham DL, Keil SD, McElroy Horne K, Pyles R, Goodrich R, Higgs S. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-290.VanlandinghamDLKeilSDMcElroyHorne KPylesRGoodrichRHiggsSPhotochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology systemTransfusion20135328429010.1111/j.1537-2995.2012.03717.x22626525Search in Google Scholar
Seltsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38(1): 43–54.SeltsamAMullerTHUVC irradiation for pathogen reduction of platelet concentrates and plasmaTransfus Med Hemother2011381435410.1159/000323845313297921779205Search in Google Scholar
Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system – An update. Transf Apher Sci 2012; 46: 221–229.SeghatchianJTolksdorfFCharacteristics of the THERAFLEX UV-Platelets pathogen inactivation system – An updateTransf Apher Sci20124622122910.1016/j.transci.2012.01.00822365926Search in Google Scholar
Faddy HM, Fryk JJ, Prow NA, Watterson D, Young PR, Hall RA, Tolksdorf, Sumian C, Gravemann U, Seltsam A, Marks DC. Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016; 56: 1548-55.FaddyHMFrykJJProwNAWattersonDYoungPRHallRATolksdorfSumian CGravemannUSeltsamAMarksDCInactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C lightTransfusion20165615485510.1111/trf.1351926926832Search in Google Scholar
Gravemann U, Handke W, Lambrecht B, Schmidt JP, Müller TH, Seltsam A. Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates Transfusion 2018; 58: 2669–2674.GravemannUHandkeWLambrechtBSchmidtJPMüllerTHSeltsamAUltraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates Transfusion2018582669267410.1111/trf.1495730267410Search in Google Scholar
Gravemann U, Handke W, Müller TH, Seltsam A. Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system. Transfusion 2019; 59; 1324–1332.GravemannUHandkeWMüllerTHSeltsamABacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation systemTransfusion2019591324–133210.1111/trf.1511930588633Search in Google Scholar
Castro E, González LM, Rubio JM, Ramiro R, Gironés N, Montero E. The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014; 54: 2207-2216.CastroEGonzálezLMRubioJMRamiroRGironésNMonteroEThe efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat plateletsTransfusion2014542207221610.1111/trf.1259824666393Search in Google Scholar
Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Müller TH, Völker U. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49(12): 2612–24.MohrHSteilLGravemannUThieleTHammerEGreinacherAMüllerTHVölkerUA novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet lightTransfusion2009491226122410.1111/j.1537-2995.2009.02334.x19682340Search in Google Scholar
Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, Lin L. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 201; 38(1): 14–19.MuftiNAEricksonACNorthAKHansonDSawyerLCorashLMLinLTreatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBCBiologicals 201381141910.1016/j.biologicals.2009.10.01919995680Search in Google Scholar
Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014; 41: 309-25.SchlenkePPathogen inactivation technologies for cellular blood components: an updateTransfus Med Hemother2014413092510.1159/000365646416410025254027Search in Google Scholar
Dupuis K, Bernard K, Jones S, Grellier P, Labaid M, Voorhis W, Barrett L, Benach J, Mansalve G, Gil-Gil H, Sawyer L. Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates. Blood 2003; 102: 816a.DupuisKBernardKJonesSGrellierPLabaidMVoorhisWBarrettLBenachJMansalveGGil-GilHSawyerLHelinx technology inactivates pathogens of emerging importance in red blood cell concentratesBlood2003102816aSearch in Google Scholar
Laughhunn A, Santa Maria F, Broult J, Lanteri MC, Stassinopoulos A, Musso D, Aubry M. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell component Transfusion 2017; 57: 779–789.LaughhunnASantaMaria FBroultJLanteriMCStassinopoulosAMussoDAubryMAmustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell component Transfusion20175777978910.1111/trf.1399328164306Search in Google Scholar
Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemoteher 2011; 38: 33-42HenschlerRSeifriedEMuftiNDevelopment of the S-303 pathogen inactivation technology for red blood cell concentratesTransfus Med Hemoteher201138334210.1159/000324458313297821779204Search in Google Scholar
Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104: 183–99.ProwseCVComponent pathogen inactivation: a critical reviewVox Sang20131041839910.1111/j.1423-0410.2012.01662.x23134556Search in Google Scholar
Lozano M, Cid J. Pathogen inactivation: coming of age. Curr Opin Hematol 2013; 20: 540–5.LozanoMCidJPathogen inactivation: coming of ageCurr Opin Hematol201320540510.1097/MOH.0b013e328365a18f24104416Search in Google Scholar
Kwon SY, Kim IS, Bae JE, Kanj JW, Cho YJ, Cho NS, Lee SW. Pathogen inactivation efficacy of Mirasol PRT system and Intercept Blood System for non-leucoreduced platelet-rich plasma derived platelets suspended in plasma. Vox Sang 2014; 107(3): 254-60.KwonSYKimISBaeJEKanjJWChoYJChoNSLeeSWPathogen inactivation efficacy of Mirasol PRT system and Intercept Blood System for non-leucoreduced platelet-rich plasma derived platelets suspended in plasmaVox Sang201410732546010.1111/vox.1215824806328Search in Google Scholar
Kaiser-Guignard J, CanelliniG, Lion N, Abonnenc M, Osselaer JC, TissotJD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014; 28: 235–41.Kaiser-GuignardJCanelliniGLion NAbonnencMOsselaerJCTissotJDThe clinical and biological impact of new pathogen inactivation technologies on platelet concentratesBlood Rev2014282354110.1016/j.blre.2014.07.00525192602Search in Google Scholar
Dupuis K, Arnold DJ, Sawyer L. High titers of Dengue Virus in platelet concentrates are inactivated by amotasalen and UVA light. Trasfusion 2012. 52 (3S): 225A.DupuisKArnoldDJSawyerLHigh titers of Dengue Virus in platelet concentrates are inactivated by amotasalen and UVA lightTrasfusion2012523S225ASearch in Google Scholar
Faddy HM, Fryk JJ, Watterson D, Young PR, Modhiran N, Muller DA, Keil SD, Goodrich RP, Marks DC. Riboflavin and ultraviolet light: impact on dengue virus infectivity. Vox Sang 2016; 111 (3): 235-241.FaddyHMFrykJJWattersonDYoungPRModhiranNMullerDAKeilSDGoodrichRPMarksDCRiboflavin and ultraviolet light: impact on dengue virus infectivityVox Sang2016111323524110.1111/vox.1241427281512Search in Google Scholar
Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877–885.RuanePHEdrichRGamppDKeilSDLeonardRLGoodrich. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and lightTransfusion20044487788510.1111/j.1537-2995.2004.03355.x15157255Search in Google Scholar
Steinmann E, Gravemann U, Friesland M, Doerrbecker J, Müller TH, Pietschmann T, Seltsam A. Two pathogen reduction technologies—methylene blue plus light and shortwave ultraviolet light—effectively inactivate hepatitis C virus in blood products. Transfusion 2013; 53(5): 1010-8.SteinmannEGravemannUFrieslandMDoerrbeckerJMüllerTHPietschmannTSeltsamATwo pathogen reduction technologies—methylene blue plus light and shortwave ultraviolet light—effectively inactivate hepatitis C virus in blood productsTransfusion20135351010810.1111/j.1537-2995.2012.03858.x22905868Search in Google Scholar
Fryk JJ, Marks DC, Hobson-Peters J, Watterson D, Hall RA, Young PR, Reichenberg S, Tolksdorf F, Sumian C, Gravemann U, Seltsam A, Faddy HM: Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light Transfusion 2017; 57; 2677–2682.FrykJJMarksDCHobson-PetersJWattersonDHallRAYoungPRReichenbergSTolksdorfFSumianCGravemannUSeltsamAFaddy HM: Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light Transfusion2017572677–268210.1111/trf.1425628718518Search in Google Scholar
El Dusouqui SA, Lanteri MC, Schwabe R, Grzesiczek A, North A, Mufti N, Sekongo YM, Pitman J, Tagny CT. Progress towards an appropriate pathogen reduction technology fo whole blood in Africa, ISBT Science Series 2019; 0, 1-13.ElDusouqui SALanteriMCSchwabeRGrzesiczekANorthAMuftiNSekongoYMPitmanJTagnyCTProgress towards an appropriate pathogen reduction technology fo whole blood in AfricaISBT Science Series20190113Search in Google Scholar
Aubry M, Laughhunn A, Santa Maria F, Lanteri MC, Stassinopoulos A, Musso D. Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione. Transfusion 2017; 57: 2888–2896.AubryMLaughhunnASantaMaria FLanteriMCStassinopoulosAMussoDPathogen inactivation of Dengue virus in red blood cells using amustaline and glutathioneTransfusion2017572888289610.1111/trf.1431828921542Search in Google Scholar
Bah A, Cardoso M, Seghatchian J, Goodrich RP. Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes. Transf Apher Sci 2018; 57: 683–688.BahACardosoMSeghatchianJGoodrichRPReflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processesTransf Apher Sci20185768368810.1016/j.transci.2018.09.00430220450Search in Google Scholar
Brecher ME, Holland PV, Pineda AA, Tegtmeier GE, Yomtovian R. Growth of bacteria in inoculated platelets: Implications for bacteria detection and the extension of platelet storage. Transfusion 2000; 40: 1308–12.BrecherMEHollandPVPinedaAATegtmeierGEYomtovianRGrowth of bacteria in inoculated platelets: Implications for bacteria detection and the extension of platelet storageTransfusion20004013081210.1046/j.1537-2995.2000.40111308.x11099657Search in Google Scholar
Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, Glebe D. Occult hepatitis B virus infection: detection and significance. Dig Dis. 2010; 28(1)9: 116-25GerlichWHBremerCSaniewskiMSchüttlerCGWendUCWillemsWRGlebeDOccult hepatitis B virus infection: detection and significanceDig Dis201028191162510.1159/00028207420460899Search in Google Scholar
Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 2012; 11(9); 1087-1101.WeaverSCOsorioJELivengoodJAChenRStinchcomb DT Chikungunya virus and prospects for a vaccineExpert Rev Vaccines20121191087110110.1586/erv.12.84356271823151166Search in Google Scholar
Müller-Steinhardt M, Müller-Kuller T, Weiss C, Menzel D, Wiesneth M, Seifried E, Klüter H. Safety and frequency of whole blood donations from elderly donors. Vox Sang 2012; 102(2):134–139.Müller-SteinhardtMMüller-KullerTWeissCMenzelDWiesnethMSeifriedEKlüterHSafety and frequency of whole blood donations from elderly donorsVox Sang2012102213413910.1111/j.1423-0410.2011.01531.x21806633Search in Google Scholar
Tauszig ME, Picker SM, Gathof BS. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. Transf Apher Sci 2012; 46: 33–37.TauszigMEPickerSMGathofBSPlatelet derived cytokine accumulation in platelet concentrates treated for pathogen reductionTransf Apher Sci201246333710.1016/j.transci.2011.10.02522119364Search in Google Scholar
Ignatova AA, Karpova OV, Trakhtman PE, Rumiantsev SA, Panteleev MA. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang 2016; 110: 244–52.IgnatovaAAKarpovaOVTrakhtmanPERumiantsevSAPanteleevMAFunctional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solutionVox Sang20161102445210.1111/vox.1236426646605Search in Google Scholar
Schubert P, Johnson L, Denese C, Marks DC, Devine DV. Ultraviolet-Based Pathogen inactivation Systems: Untangling the Molecular Targets Activated in Platelets. Front Med 2018; 5: 129.SchubertPJohnsonLDeneseCMarksDCDevineDVUltraviolet-Based Pathogen inactivation Systems: Untangling the Molecular Targets Activated in PlateletsFront Med2018512910.3389/fmed.2018.00129594932029868586Search in Google Scholar
P. Sandgren, F. Tolksdorf W. G. Struff, H. Gulliksson. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method. Vox Sang 2011; 101: 35–43.SandgrenP.TolksdorfF.G. StruffW.GullikssonH.In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets methodVox Sang2011101354310.1111/j.1423-0410.2010.01454.x21175668Search in Google Scholar
Dijkstra-Tiekstra MJ, Kuipers W, Setroikromo AC, Wildt-Eggen JD. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates. Transfusion 2008; 48: 2114–2121.Dijkstra-TiekstraMJKuipersWSetroikromoACWildt-EggenJDPlatelet capacity of various platelet pooling systems for buffy coat-derived platelet concentratesTransfusion2008482114212110.1111/j.1537-2995.2008.01849.x18647365Search in Google Scholar
Johnson L, Hyland R, Tan S, Tolksdorf N, Sumian C, Seltsam A, Marks D. In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation. Transfus Med Hemother 2016; 43: 190–197.JohnsonLHylandRTanSTolksdorfNSumianCSeltsamAMarksDIn vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen InactivationTransfus Med Hemother20164319019710.1159/000441830492447027403091Search in Google Scholar
Mastroianni MA, Llohn AH, Akkök CA, Skogheim R, Ødegaard ER, Jenssen Nybruket M, Flesland A, Mousavi SA. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets. Transf Apher Sci 2013; 49: 285–290.MastroianniMALlohnAHAkkökCASkogheimRØdegaardERJenssenNybruket MFleslandAMousaviSAEffect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis plateletsTransf Apher Sci20134928529010.1016/j.transci.2013.06.00923820429Search in Google Scholar
van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79: 206–14.vanRhenen DJVermeijJMayaudonVHindCLinLCorashLFunctional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coatsVox Sang2000792061410.1046/j.1423-0410.2000.7940206.xSearch in Google Scholar
Schubert P, Culibrk B, Coupland D, Scammell K, Gyongyossy-Issa M, Devine DV. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397–408.SchubertPCulibrkBCouplandDScammellKGyongyossy-IssaMDevineDVRiboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storageTransfusion20125239740810.1111/j.1537-2995.2011.03287.x21827504Search in Google Scholar
Van Aelst B, Devloo R, Vandekerckhove P, Compernolle V, Feys HB. Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro. Transfusion 2015; 55: 2404–14.VanAelst BDevlooRVandekerckhovePCompernolleVFeysHBUltraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitroTransfusion20155524041410.1111/trf.1313725912149Search in Google Scholar
Bashir S, Cookson P, Wiltshire M, Hawkins L, Sonoda L, Thomas S, Seltsam A, Tolksdorf F, Williamson LM, Cardigan R. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013; 53: 990–1000.BashirSCooksonPWiltshireMHawkinsLSonodaLThomasSSeltsamATolksdorfFWilliamsonLMCardiganRPathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of plateletsTransfusion201353990100010.1111/j.1537-2995.2012.03854.x22905813Search in Google Scholar
Reid S, Johnson L, Woodland N, Marks DC. Pathogen reduction treatment of buffycoat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012; 52: 2094–103.ReidSJohnsonLWoodlandNMarksDCPathogen reduction treatment of buffycoat platelet concentrates in additive solution induces proapoptotic signalingTransfusion201252209410310.1111/j.1537-2995.2011.03558.x22320126Search in Google Scholar
Chen Z, Schubert P, Bakkour S, Culibrk B, Busch MP, Devine DV. p38 mitogen-activated protein kinase regulates mitochondrial function and microvesicle release in riboflavin- and ultraviolet light-treated apheresis platelet concentrates. Transfusion 2017; 57: 1199–207.ChenZSchubertPBakkourSCulibrkBBuschMPDevineDVp38 mitogen-activated protein kinase regulates mitochondrial function and microvesicle release in riboflavin- and ultraviolet light-treated apheresis platelet concentratesTransfusion201757119920710.1111/trf.1403528236306Search in Google Scholar
Rukoyatkina N, Mindukshev I, Walter U, Gambaryan S. Dual role of the p38/MAPK/cPLA2 pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonists. Cell Death & Disesase 2013; 4, e931RukoyatkinaNMindukshevIWalterUGambaryanSDual role of the p38/MAPK/cPLA2 pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonistsCell Death & Disesase20134e93110.1038/cddis.2013.459384733524263105Search in Google Scholar
Zharinov S, Shiva S. Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease. Biochem Soc Trans 2013; 41(1): 118-23.ZharinovSShivaSPlatelet mitochondrial function: from regulation of thrombosis to biomarker of diseaseBiochem Soc Trans20134111182310.1042/BST2012032723356269Search in Google Scholar
Bakkour S, Chafets DM, Wen L, Dupuis K, Castro G, Green JM, Stassinopoulos A, Busch MP, Lee TH. Assessment of nucleic acid modification induced by amotosalen and ultraviolet a light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion 2016; 56: 410–20.BakkourSChafetsDMWenLDupuisKCastroGGreenJMStassinopoulosABuschMPLeeTHAssessment of nucleic acid modification induced by amotosalen and ultraviolet a light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNATransfusion2016564102010.1111/trf.1336026446053Search in Google Scholar
Simmons JD, Lee YL, Pastukh VM, Capley G, Muscat CA, Muscat DC, Marshall ML, Brevard SB, Gillespie MN. Potential contribution of mitochondrial DNA damage associated molecular patterns in transfusion products to the development of acute respiratory distress syndrome after multiple transfusions. J Trauma Acute Care Surg 2017; 82: 1023–9.SimmonsJDLeeYLPastukhVMCapleyGMuscatCAMuscatDCMarshallMLBrevardSBGillespieMNPotential contribution of mitochondrial DNA damage associated molecular patterns in transfusion products to the development of acute respiratory distress syndrome after multiple transfusionsJ Trauma Acute Care Surg2017821023910.1097/TA.0000000000001421547206328301393Search in Google Scholar
Canault M, Duerschmied D, Brill A, Stefanini L, Schatzberg D, Cifuni SM, Bergmeier W, Wagner DD. p38 mithoge-activated protein kinase activation during platelet storage: consequnce for patelet recovery and hemostatic function in vivo. Blood 2010; 115(9): 1835-1842.CanaultMDuerschmiedDBrillAStefaniniLSchatzbergDCifuniSMBergmeierWWagnerDDp38 mithoge-activated protein kinase activation during platelet storage: consequnce for patelet recovery and hemostatic function in vivoBlood201011591835184210.1182/blood-2009-03-211706283281119965619Search in Google Scholar
Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK,Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. Journal of thrombosis and haemostasis 2007; 5: 1530-1537.GardinerEEKarunakaranDShenYArthurJFAndrewsRKBerndtMCControlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinasesJournal of thrombosis and haemostasis200751530153710.1111/j.1538-7836.2007.02590.x17445093Search in Google Scholar
Moshfegh K, Lengweiler S, Häner M, Aebi U, Steiner B, Beer JH. Fine structural and functional consequences of deglycosylation of the platelet adhesion receptor GPIb-IX (CD 42b). Biochem Biophys Res Commun 1998; 249(3): 903-909.MoshfeghKLengweilerSHänerMAebiUSteinerBBeerJHFine structural and functional consequences of deglycosylation of the platelet adhesion receptor GPIb-IX (CD 42b)Biochem Biophys Res Commun1998249390390910.1006/bbrc.1998.91259731234Search in Google Scholar
Hechler B, Ohlmann P, Chafey P, Ravanat C, Eckly A, Maurer E, Mangin P, Isola H, Cazenave JP, Gachet C. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013 ;53(6): 1187-1200.HechlerBOhlmannPChafeyPRavanatCEcklyAMaurerEManginPIsolaHCazenaveJPGachetCPreserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivationTransfusion20135361187120010.1111/j.1537-2995.2012.03923.x23067365Search in Google Scholar
Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica 2017; 102(10): 1650-60.StivalaSGobbatoSInfantiLReinerMFBonettiNMeyerSCCamiciGGLüscherTFBuserABeerJHAmotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearanceHaematologica20171021016506010.3324/haematol.2017.164137562284928729303Search in Google Scholar
McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Bichholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104(5): 1534–41. doi:10.1182/ blood-2003-12-4443.McCulloughJVesoleDHBenjaminRJSlichterSJPinedaASnyderEStadmauerEALopez-PlazaICoutreSStraussRGGoodnoughLTFrideyJLRaifeTCableRMurphySHowardF 4thDavisKLinJSMetzelPCorashLKoutsoukosALinLBichholzDHConlanMGTherapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trialBlood2004104515344110.1182/blood-2003-12-444315138160Open DOISearch in Google Scholar
Estcourt LJ, Malouf R, Hopewell S, Trivella M, Doree C, Stanworth SJ, Murphy MF. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2017; 7: CD009072. doi:10.1002/14651858.CD009072.pub3.EstcourtLJMaloufRHopewellSTrivellaMDoreeCStanworthSJMurphyMFPathogen-reduced platelets for the prevention of bleedingCochrane Database Syst Rev20177CD00907210.1002/14651858.CD009072.pub3555887228756627Open DOISearch in Google Scholar
Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49.BenjaminRJMcCulloughJMintzPDSnyderESpotnitzWDRizzoRJWagesDLinJSWoodLCorashLConlanMGTherapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patientsTransfusion20054517394910.1111/j.1537-2995.2005.00583.x16271099Search in Google Scholar
Wiltshire M, Meli A, Schott MA, Erickson A, Mufti N, Thomas S, Cardigan R, Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfusion Medicine 2016; 26: 208–214.WiltshireMMeliASchottMAEricksonAMuftiNThomasSCardiganRQuality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivationTransfusion Medicine20162620821410.1111/tme.1229827006102Search in Google Scholar
Winter KM, Johnson L, Kwok M, Vidovic D, Hyland RA, Mufti N, Erickson A, Marks DC. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 2014; 54: 1798–1807.WinterKMJohnsonLKwokMVidovicDHylandRAMuftiNEricksonAMarksDCRed blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatmentTransfusion2014541798180710.1111/trf.1254524617658Search in Google Scholar
Aydinok Y, Piga A, Origa R, Mufti N, Erickson A, North A, Waldhaus K, Ernst C, Lin J, Huang N, Benjamin RJ, Laurence Corash L. Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia. Br J Haemat 2019, 186, 625–636.AydinokYPigaAOrigaRMuftiNEricksonANorthAWaldhausKErnstCLinJHuangNBenjaminRJLaurenceCorash LAmustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemiaBr J Haemat201918662563610.1111/bjh.15963677195431148155Search in Google Scholar
Brixner B, Kiessling A, Madlener K, Müller MM, Leibacher J, Dombos S, Weber I, Pfeiffer H, Geisen C, Schmidt M, Henschler R, North A, Huang N, Mufti N, Erickson A, Ernst C, Rico S, Benjamin RJ, Corash LM, Seifried E. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery. Transfusion 2018; 58: 905–916.BrixnerBKiesslingAMadlenerKMüllerMMLeibacherJDombosSWeberIPfeifferHGeisenCSchmidtMHenschlerRNorthAHuangNMuftiNEricksonAErnstCRicoSBenjaminRJCorashLMSeifriedERed blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgeryTransfusion20185890591610.1111/trf.1452829498049Search in Google Scholar
Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, Huang N, Mufti N, Erickson A, S. Rico S, Corash L, Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017; 112: 210–218.CancelasJAGottschallJLRuggNGraminskeSSchottMANorthAHuangNMuftiNEricksonAS. Rico S, Corash L, Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre studyVox Sang201711221021810.1111/vox.1250028220519Search in Google Scholar
Cancelas JA, Slichter SJ, Rugg N, Gayle Pratt, P, Nestheide S, Corson J, Pellham E, Huntington M, Goodrich RP. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage. Transfusion 2017; 57: 1218–1225.CancelasJASlichterSJRuggNGaylePrattPNestheide SCorsonJPellhamEHuntingtonMGoodrichRPRed blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storageTransfusion2017571218122510.1111/trf.1408428369971Search in Google Scholar
North AK, Henschler R, Geisen C, Garratty G, Arndt PA, Kattamis A, cohen A, Piga A, Arslan O, Galanello R. Evaluation of naturally occurring antibodies to pathogen inactivated red blood cells. Transfusion (2010) 50(Suppl):38A.NorthAKHenschlerRGeisenCGarrattyGArndtPAKattamisAcohenAPigaAArslanOGalanelloREvaluation of naturally occurring antibodies to pathogen inactivated red blood cellsTransfusion201050Suppl38ASearch in Google Scholar
Łetowska M, Przybylska Z, Piotrowski D, Lachert E, Rosiek A, Rzymkiewicz L, Cardoso M. Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period. Transfusion 2016; 56; S39–S44.ŁetowskaMPrzybylskaZPiotrowskiDLachertERosiekARzymkiewiczLCardosoMHemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 periodTransfusion201656S39–S4410.1111/trf.1333027001360Search in Google Scholar
Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasonglès P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand HA, Herving T, de Castro EF, Lozano AM, Navarro L, Puig L, Almazàn C, Maclennan S, Cardigan R, Franklin IM, Prowse C. Pathogen inactivation of platelet concentrates. Vox Sang 2010; 99: 85–95.ReesinkHWPanzerSMcQuiltenZKWoodEMMarksDCWendelSTrigoFBiaginiSOlynthoSDevineDVMumfordICazenaveJPRasonglèsPGarraudORichardPSchoonemanFVezonGAlRadwan RBrandHAHervingTdeCastro EFLozanoAMNavarroLPuigLAlmazànCMaclennanSCardiganRFranklinIMProwseCPathogen inactivation of platelet concentratesVox Sang201099859510.1111/j.1423-0410.2010.01319.x20230599Search in Google Scholar
